Author's response to reviews

Title: An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and literature review

Authors:

Samir M Al-Minshawy (Sammoner2@yahoo.com)
Abdel-Azeem M El-Mazary (abdelazeemhemed@yahoo.com)

Version: 4 Date: 24 October 2013

Author's response to reviews: see over
Dear professor,

Great thanks for you. We had revised all reviewer's comments and addressed the comments in a revised manuscript and a cover letter giving point by point response to the concerns as follow:

1- We included the study design in our title.

2- We included keywords after the Abstract section.

3- We included a list of abbreviations used in the manuscript and their meanings after the Conclusions section.

4- We included an acknowledgement section at the end of the manuscript.

5- We included a figure title and legend section after the reference list.

6- As regards the chance association of a waxing-waning clinical course or a placebo response, we had explained the effect of treatment withdrawal in the abstract and main text.

7- We revised and mentioned that the age of presentation of our case at the age of 3 is not the only case as reported by other families and we addressed the references of this.

8- We already cited and mentioned all references reported by the reviewers in its context and references list.

9- In the discussion we pointed out that some patients respond well to treatment with carbamazepine, and their mutations have been shown the sensitive the Nav1.7 channel to this drug.

10- We addressed that recent studies have indicated that it is possible to predict the response of patients with EM to treatment with sodium channel blockers on the basis of atomic-level structural modeling.

11- We changed (very early onset of age) to (early age) in the Abstract and main text sections.

12- We described the skin biopsy in the 'case report' section.

13- We clarified the method of research to prove that this is the first Egyptian case through PubMed search along the last 10 years.

14- As regards the (genetic testing) we could not do it as it is expensive and we depended upon the clear history and clinical picture of the case in the diagnosis, adding that the genetic study may be more valuable in studies dealing with pharmacological response to different drugs on a large scale.

Dr. Abdel-Azeem El-Mazary